Synthesis of new thienyl ring containing HIV-1 protease inhibitors: Promising preliminary pharmacological evaluation against recombinant HIV-1 proteases

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1451-1457

  Bonini, Carlo ^a   Chiummiento, Lucia ^a   De Bonis, Margherita ^a   Blasio, Nadia Di ^a   Funicello, Maria ^a   Lupattelli, Paolo ^a   Pandolfo, Rocco ^a   Tramutola, Francesco ^a   Berti, Federico ^b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL GROUP; N 1 [1 (BENZO[B]THIOPHEN 2 YL) 4 [(3S,4AS,8AS) 3 (TERT BUTYLCARBAMOYL)OCTAHYDROISOQUINOLIN 2(1H) YL] 3 HYDROXYBUTAN 2 YL] 2 (QUINOLINE 2 CARBOXAMIDO)SUCCINAMIDE; N TERT BUTYL 2 [2 HYDROXY 3 (3 HYDROXY 2 METHYLBENZAMIDO) 4 (4 PHENYLTHIOPHEN 2 YL)BUTYL]DECAHYDROISOQUINOLINE 3 CARBOXAMIDE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; THIENYL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION;

ASPARAGINE; HIV PROTEASE; HIV PROTEASE INHIBITORS; MUTATION; NELFINAVIR; QUINOLINES; RECOMBINANT PROTEINS; SAQUINAVIR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649205622     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm900846f     Document Type: Article

References (30)

1. De Clerck, E. New approaches toward Anti-HIV chemotherapy. J. Med. Chem. 2005, 48, 1297-1313. (Pubitemid 40364540)
2. (a) Sepkowitz, K. A. AIDS - The first 20 years. N. Engl. J. Med. 2001, 344, 1764-1772.
3. (b) Cihlar, T.; Bischofberger, N. Recent developments in antiretroviral therapies. Annu. Rep. Med. Chem. 2000, 35, 177-189.
4. (c) Flexner, C. W. Pharmacology of Drug Interactions of HIV Protease Inhibitors. In Protease Inhibitors in AIDS Therapy; Ogden, R. C., Flexner, C. W., Eds.; Marcel Dekker: New York, 2001; pp 139-160.
5. (a) Hammer, S. M.; Squires, H. E.; Hughes, M. D.; Grimes, J. M.; Demeter, L. M.; Currier, J. S.; Eron, J. J., Jr.; Feinberg, J. E.; Balfour, H. H.; Deyton, L. R.; Chodakewitz, J. A.; Fischl, M. A. A controlled, trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 1997, 337, 725-733.
6. (b) Collier, A. C.; Coombs, R. W.; Schoenfeld, D. A.; Bassett, R. L.; Timpone, J.; Baruch, A.; Jones, M.; Facey, K.; Whitcare, C.; McAuliffe, V. J.; Friedman, H. M.; Merigan, T. C.; Reichman, R. C.; Hooper, C.; Corey, L. Treatment of human immunodeficiency virus infection with, saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 1996, 334, 1011-1017. (Pubitemid 26124452)
7. (c) Cameron, D. W.; Heat-Chiozzi, M.; Danner, S.; Cohen, C.; Kravcik, S.; Maurath, C.; Sun, E.; Henry, D.; Rode, R.; Potthoff, A.; Leonard, J. Randomised placebo-controlled trial of ritonavir an advanced HIV-1 disease. Lancet 1998, 351, 543-549. (Pubitemid 28077559)
8. (d) Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Gonzales, C.; McMahon, D.; Richman, D. D.; Valentine, F. T.; Jonas, L.; Meibohm, A.; Emini, E. A.; Chodakewitz, J. A. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 1997, 337, 734-739.
9. Freire, E. Overcoming HIV-1 resistance to protease inhibitors. Drug Discovery Today: Dis. Mech. 2006, 3, 281-286. (Pubitemid 44356304)
10. Rusconi, S.; Viganò, O. New HIV protease inhibitors for drugresistant viruses. Therapy 2006, 3, 79-88.
11. (a) Tomasselli, A. G.; Heinrikson, R. L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta 2000, 1477, 189-214.
12. (b) Wlodawer, A.; Gustchina, A. Structural and biochemical studies of retroviral proteases. Biochim. Biophys. 2000, 1477, 16-34.
13. Gante, J. Peptidomimetics - tailored enzyme inhibitors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699-1720.
14. (a) Corral, C.; Lissavetzky, J.; Manzanares, I.; Danas, V.; Exposito-Orta, M. A.; Conde, J. A. M.; Sanchez-Mateo, C. C. Synthesis and preliminary pharmacological evaluation of thiophene analogues of viloxazine as potential antidepressant drugs. Bioorg, Med, Chem. 1999, 7, 1349-1359.
15. (b) Zhang, A.; zhou, G.; Rong, S.-B.; Johnson, K. M.; Zang, M.; Kozikowsky, A. P. Thiophene derivatives: a new series of potent norepinephrine and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 993-995.
16. (c) Uckun, F. M.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Mao, C.; Venkatachalam, T. K. N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett. 1999, 9, 3411-3416.
17. Mühlman, A.; Classon, B.; Hallberg, A.; Samuelsson, B. Synthesis of potent C-symmetric, diol based HIV-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1′ substituents. J. Med, Chem. 2001, 44, 3402-3406.
18. Ghosh, A. K.; Bilcer, G.; Schiltz, G. Syntheses of FDA approved HIV protease inhibitors. Synthesis 2001, 15, 2203-2229. (Pubitemid 33081858)
19. (a) Bonini, C.; Chiummiento, L.; De Bonis, M.; Funicello, M.; Lupattelli, P. Synthesis of a first thiophene analog of the HIV protease inhibitor nelfinavir. Tetrahedron Lett. 2004, 45, 2797-2799. (Pubitemid 38317150)
20. (b) Bonini, C.; Chiummiento, L.; De Bonis, M.; Funicello, M.; Lupattelli, P.; Suanno, G.; Berti, F.; Campaner, P. Synthesis, biological activity and modeling studies of two novel anti HIV Pr inhibitors with a thiophene containing hydroxyethylamino core. Tetrahedron 2005, 61, 6580-6589.
21. (c) Bonini, C.; Funicello, M.; Lupattelli, P.; Chiummiento, L.; De Bonis, M. Inibitori di HIV-1 Proteasi. Italian. Patent Application MI2008A000415, 2008.
22. Bonini, C.; Chiummiento, L.; De Bonis, M.; Funicello, M.; Lupattelli, P.; Pandolfo, R. Application of Sharpless asymmetric dihydroxylation to thienyl- and benzothienyl acrylates and crotonates. Tetrahedron: Asymmetry 2006, 17, 2919-2924. (Pubitemid 44820831)
23. Unfortunately, although expected, the same approach gave the wrong regioisomer 9 in the case of sulfite 6a, due to the higher electrophilicity of α-carbon of sulfinyl esters. Chemical Equetion Presentation.
24. Napolitano, E.; Fiaschi, R.; Mastrorilli, E. Halogenative deoxygenation of ketones: vinyl bromides and/or gem-dibromides by cleavage of 1,3-benzodioxoles (ketone phenylene acetals) with boron tribromide. Synthesis 1986, 122-125.
25. Mesylate 12a was not isolated, and was used, in the subsequent reaction as a crude.
26. (a) Gulnik, S. V.; Suvorov, S. I.; Liu, B.; Yu, B.; Anderson, B.; Mitsuya, H.; Erickson, J. B. Kinetic characterization and crossresistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry, 1995, 34, 9282-9287.
27. (b) Svicher, V.; Cherini-Silberstein, F.; Erba, F.; Santoro, M.; Gori, C.; Bellocchi, M. C; Giannella, S.; Trotta, M. P.; Monforte, A. D.; Antinori, A.; Pemo, C. F. Novel human immunodeficiency vims type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicroh. Azents CAemother. 2005, 49 (5), 2015-2025.
28. 50 measurements differs from that used as reference for the mutant test, due to their different commercial sources (Bioczech and Bachern, respectively).
29. Mosebi, S.; Morris, L.; Dirr, H. W.; Sayed, Y. Active-site mutations in the South African human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic sudy. J. Virol. 2008, 82, 11476-11479.
30. Kovalevsky, A. Y.; Ghosh, A. K.; Weber, I. T. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. J. Med. Chem. 2008, 51, 6599-6603.